What is Kidney Transplant Phase 3 Belatacept BENEFIT?

Category: Others

false

See also: Clinical Trial

NCT00256750 is belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial. Other study IDs include: IM103-008, BENEFIT.

Purpose
Patients
Patients with evaluations
Perceived effectiveness
Patients
Patients with evaluations

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects of Kidney Transplant Phase 3 Belatacept BENEFIT

Severe
0
Moderate
0
Mild
0
None
1

Dosages

Most common dosages (by patients currently using Kidney Transplant Phase 3 Belatacept BENEFIT)
Dosage
500 mg monthly
Patients
1
Dosage
750 mg monthly
Patients
1
Dosage
500 mg every other week
Patients
1

Adherence


Always
Patients
1
100%
Usually
Patients
0
0%
Sometimes
Patients
0
0%
Never
Patients
0
0%

Burden


Very
Patients
0
0%
Somewhat
Patients
0
0%
A little
Patients
0
0%
Not at all
Patients
1
100%

Cost per month


Cost per month
$200+
Patients
0
0%
Cost per month
$100-199
Patients
0
0%
Cost per month
$50-99
Patients
0
0%
Cost per month
$25-49
Patients
0
0%
Cost per month
< $25
Patients
0
0%
Cost per month
Not specified
Patients
1
100%
Last updated:
There are no evaluations for Kidney Transplant Phase 3 Belatacept BENEFIT.